RegeneRx Biopharmaceuticals Inc (RGRX): RegeneRx Joint Venture Announces Efficac...

Reply Private New

Replies (4) Next 10 Prev Next

Send PM Follow Ignore

Re: The Night Stalker post# 255

Thursday, 05/14/2020 7:34:44 AM

Thursday, May 14, 2020 7:34:44 AM

RegeneRx Joint Venture Announces Efficacy Results of Neurotrophic Keratopathy Phase 3 Clinical Trial with RGN-259
ReGenTree Also Developing New NK Ophthalmic Formulation
PR Newswire
https://www.otcmarkets.com/stock/RGRX/news/RegeneRx-Joint-Venture-Announces-Efficacy-Results-of-Neurotrophic-Keratopathy-Phase-3-Clinical-Trial-with-RGN-259?id=262010

Keep Last Read

Replies (4) Next 10 Prev Next

Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 08/14/2023 08:01:40 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2023 07:57:35 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/11/2023 09:13:55 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2023 09:19:09 PM
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 07/06/2023 08:35:03 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/06/2023 08:30:14 PM

InvestorsHub NewsWire

Only $200 per official company press release!